Evotec SE (EVT.DE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Paul Hitchin | Chief Financial Officer | -- | -- | -- |
| Mr. Volker Braun | Executive VP and Head of Global Investor Relations & ESG | -- | -- | -- |
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance | -- | -- | 1972 |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations | 116k | -- | 1950 |
| Dr. David Hallet | Executive Vice President | -- | -- | -- |
| Uwe Andag | EVP Head of Metabolic Diseases | -- | -- | -- |
| Ms. Christiane Honisch | SVP Head of Diagnostics | -- | -- | -- |
| Claudia Karnbach | Executive VP, Global Head of Strategic Partnerships and Alliances & Site Head of Hamburg | -- | -- | -- |
| Dr. Philip Boehme | Executive VP of Partnering & Transformation | -- | -- | -- |
| Mr. Christian Buhlmann | Executive VP & Head of Global BD Development | -- | -- | -- |
Evotec SE
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 4,740
Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio-metabolic disorders; and animal and women health. It has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore, as well as partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB; Bayer, Novo Nordisk, Eli Lilly, and Novartis company for kidney disease; and Sandoz, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Corporate Governance
Upcoming Events
May 7, 2025 at 5:20 AM UTC
Evotec SE Earnings Date
Recent Events
Recent Events Information Not Available